NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis

Xiaoman Bi1,3,4,7†, Qing Zhang2†, Lei Chen1,3,4†, Dan Liu1,3, Yueying Li1,3, Xiaoxi Zhao2, Ya Zhang1,3,4, Liping Zhang5, Jingkun Liu1,3,4, Chaoyi Wu1,3,4, Zhigang Li2, Yunze Zhao5, Honghao Ma5, Gang Huang6, Xin Liu1,3,4*, Qian-fei Wang1,3,4* and Rui Zhang5*

Abstract

Hemophagocytic lymphohistiocytosis (HLH), particularly primary HLH (pHLH), is a rare, life-threatening disease. Germline genetic deficiency of 12 known HLH genes impairs cytotoxic degranulation in natural killer (NK) cells or cytotoxic T lymphocytes (CTLs) and contributes to pHLH development. However, no pathogenic mutations in these HLH genes are found in nearly 10% of HLH patients, despite a strong suspicion of pHLH, suggesting that the underlying genetic basis of HLH is still unclear. To discover novel susceptibility genes, we first selected 13 children with ppHLH (presumed primary HLH patients in the absence of detectable known HLH gene variants) and their parents for initial screening. Whole-genome sequencing (WGS) in one trio and whole-exome sequencing (WES) in twelve trios revealed that two ppHLH patients carried biallelic NBAS variants, a gene that is involved in Golgi-to-endoplasmic reticulum (ER) retrograde transport upstream of the degranulation pathway. Additionally, two candidate genes, RAB9B and KLC3, showed a direct relationship with known HLH genes in protein-protein interaction (PPI) network analysis. We analyzed NBAS, RAB9B, KLC3 and known HLH genes in an independent validation cohort of 224 pediatric HLH patients. Only biallelic NBAS variants were identified in three patients who harbored no pathogenic variants in any of the known HLH genes. Functionally, impaired NK-cell cytotoxicity and degranulation were revealed in both NBAS biallelic variant patients and in an NBAS-deficient NK-cell line. Knockdown of NBAS in an NK-cell line (IMC-1) using short hairpin RNA (shRNA) resulted in loss of lytic granule polarization and a decreased number of cytotoxic vesicles near the Golgi apparatus. According to our findings, NBAS is the second most frequently mutated gene (2.11%) in our...
To the Editor,

Hemophagocytic lymphohistiocytosis is a rare syndrome characterized by systemic inflammation, hypercytokinemia and multiorgan failure [1]. Primary HLH typically occurs in early childhood and is caused by pathogenic variants in 12 known HLH genes [1, 2]. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only definitive curative therapy for pHLH [3, 4]. According to the HLH-2004 protocol, variants in HLH genes serve as independent diagnostic criteria for pHLH and a guide to help select treatment options [5]. However, in nearly ten percent of patients clinically strongly suggested to have pHLH, no pathogenic variants in known HLH genes are present [6, 7].

In this study, we performed WES (n = 12) or WGS (n = 1) in 13 ppHLH parent-child trios (strongly suspected pHLH cases despite lacking a confirmed genetic diagnosis). A total of 6,717,749 variants were successfully called across the 13 ppHLH patients (Fig. 1a). After filtering, we identified 58 genotypes that may contribute to pHLH (Additional file 1: Methods and Fig. S1, Additional file 2: Table S1). The majority of the genes annotated by these variants appeared to be patient specific, except for TMEM236 and NBAS. In PPI network analysis, three genes (RAB9B, KLC3 and AP3D1) showed molecular relationships with known HLH genes (Additional file 1: Fig. S2). Finally, only the recurrently mutated gene NBAS and two genes (RAB9B and KLC3) from the PPI network remained after Sanger confirmation and pedigree

Fig. 1 Identification and bioinformatic characterization of NBAS bi-allelic variants. a Schematic representation of gene prioritization and validation strategies applied in this study. NBAS genotypes of two ppHLH families in the discovery stage (b) and three families in the replication stage (c). Closed symbols indicate affected patients, and open symbols indicate unaffected family members. d Schematic diagrams of the genomic location of NBAS. e Distribution of NBAS variants identified in this study (top) and the evolutionary conservation of mutated amino acids in the NBAS protein among different species (bottom). All 52 exons of the NBAS gene (reference sequence NM_015909) and two known protein domains of the NBAS protein are represented. ppHLH, presumed primary HLH; WES, whole-exome sequencing; WGS, whole-genome sequencing.
segregation analysis (Fig. 1b and Additional file 1: Fig. S3).

To examine whether variants in the three candidate genes are present in other HLH patients, we extended our genetic study to a validation cohort of 224 pediatric HLH patients (Additional file 2: Tables S2 and S3). Variants in only NBAS were found in three additional HLH children, with confirmation by Sanger sequencing in a family setting (Fig. 1c). Collectively, a total of five patients in our study carried NBAS biallelic variants (Fig. 1d–e and Additional file 2: Table S4). The estimated frequency of NBAS variants among the pediatric HLH patients was 2.11%, which is lower than that of PRF1 but higher than that of the other 11 known pHLH genes (Additional file 2: Tables S5 and S6). The main clinical characteristics at baseline of all pHLH patients, including the 5 with NBAS variants, are summarized in Additional file 2: Table S7.

To explore the functional relevance of NBAS variants in HLH, we focused on patient P007, who presented with recurrent HLH as soon as therapy was discontinued after complete remission (Fig. 2a). Prompted by a suspicion of pHLH, functional investigations were performed after her second relapse. For both NK cells and CTLs from P007, cytotoxic function and degranulation were defective compared with those of her healthy parents (heterozygous carriers of NBAS); however, progressive recovery in these functions occurred after she received haploidentical HSCT from her father (Fig. 2b). This is consistent with the notion that HLH gene variants reported to date are generally loss-of-function. Therefore, we performed RNA interference of NBAS by using two different shRNAs in the NK-cell line IMC-1, and the NBAS shRNA-targeted (shNBAS) cells showed impaired cytotoxicity and degranulation (Fig. 2c–f and Additional file 1: Figs. S4 and S5), consistent with the abnormalities in the cells from patients.

Considering that NBAS is known to be essential for NK-cell cytolytic function and Golgi-to-ER retrograde transport [8–11], NBAS may function upstream of the lymphocyte degranulation process. As shown in Fig. 2g–h, knockdown of NBAS decreased the number of cytotoxic vesicles, particularly near the Golgi apparatus. Furthermore, shNBAS IMC-1 cells exhibited significantly decreased expression of AP3B1, an important protein upstream of the known degranulation pathway involved in the transport of cytotoxic vesicles from the Golgi (Fig. 2i and Additional file 1: Fig. S6). Taken together, these findings suggest that NBAS defects disrupt the transport and recycling of proteins or vesicles between the ER and Golgi apparatus and then impact the downstream cytotoxic vesicle transport and degranulation cascades involved in HLH (Fig. 2j).

Biallelic mutations in NBAS have been related to a wide spectrum of symptoms, whereas mutations occurring at Sec39 domain and C-terminal mainly associated with liver failure and multisystemic features, respectively [12]. NBAS mutated HLH in this study was not associated with these clinical manifestations, and 90% of mutations identified clustered within the latter region of the Sec39 and C-terminal domains. It remains to be determined whether differences in mutation spectrum contribute to differential phenotypic manifestations. Collectively, our data provide compelling evidence that the recurrent mutated gene NBAS, known for being involved in transport between the Golgi and ER, is an HLH-predisposing gene that may play a role upstream of the known degranulation pathway in NK cells.
Fig. 2 (See legend on previous page.)
Acknowledgments
We truly appreciate the supports from all staffs of Chinese Academy of Sciences Precision Medicine Initiative (CASPMI) project for internal cohort data sharing.

Author contributions
XB, QZ, LC, XL, QW and RZ designed the research; RZ and ZL were responsible for diagnosis and enrollment of patients; QZ, XZ and LZ collected patient sample and clinical information; XB and QZ analyzed the clinical data; X8 and DL performed bioinformatic analysis; QZ, LC, YL, and JL performed the functional analysis; LC, XZ, YZ and CW extracted genomic DNA from patients for sequencing; XB, QZ, LC, XL, QW and RZ drafted the manuscript; GH provided expertise and feedback in functional analysis and manuscript; YZ and HM provided support in the project. All the authors reviewed and approved the manuscript.

Funding
This work was supported by National Key Research and Development Program of China (2021YFC2500300 to Dr. XL); The National Natural Science Foundation of China (81890092 to Dr. QW, 81570173 and 81873454 to Dr. XL, 81800189 to QZ); Beijing Natural Science Foundation (M21022 to Dr. QW); The Special Fund of The Pediatric Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals (No. XITZ20180202 to RZ); Beijing Municipal Science & Technology Commission (No. Z1710000107050 to RZ).

Availability of data and materials
The datasets generated and analyzed during the current study are available in the Genome Sequence Archive in National Genomics Data Center, Beijing Institute of Genomics (China National Center for Bioinformation). Informed consent of Genomics (China National Center for Bioinformation). Informed consent was obtained from all study participants.

Declarations
Ethics approval and consent to participate
The study was approved by the Institutional Review Board of Beijing Institute of Genomics (China National Center for Bioinformation). Informed consent was obtained from all study participants.

Consent for publication
This manuscript has not been published elsewhere in part or in entirety and is not under consideration by another journal.

Competing interests
The authors declare that they have no competing interests.

Author details
1CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, China. 2Hematologic Disease Laboratory, Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China. 3China National Center for Bioinformatics, Beijing 100004, China. 4University of Chinese Academy of Sciences, Beijing 100040, China. 5Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China. 6Divisions of Pathology and Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA. 7Key Laboratory of Tropical Translational Medicine of Ministry of Education, College of Biomedical Information and Engineering, Hainan Medical University, Haikou 517119, China.

Received: 10 May 2022   Accepted: 12 July 2022

Published online: 28 July 2022

References
1. Chandrakasan S, Filipovich AH. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment. J Pediatr. 2013;163(5):253–9. https://doi.org/10.1016/j.jpeds.2013.06.053.
2. Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. Blood. 2020;135(16):1332–43. https://doi.org/10.1182/blood.2019000936.
3. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041–52. https://doi.org/10.1182/blood-2011-03-278127.
4. Trottestam H, Home A, Arico M, Egerer RM, Filipovich AH, Gadner H, et al. Chemoinmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577–84. https://doi.org/10.1182/blood-2011-06-356261.
5. Henter JI, Horne A, Arico M, Egerer RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31. https://doi.org/10.1002/pbc.21039.
6. Cetica V, Sieni E, Pende D, Danesino C, De Fusco C, Locatelli F, et al. Genetic predisposition to hemophagocytic lymphohistiocytosis: report on 500 patients from the Italian registry. J Allergy Clin Immunol. 2016;137(1):188-96.e4. https://doi.org/10.1016/j.jaci.2015.06.048.
7. Chadwick RS, de Leval L, Scott AM, Serfling M. The genetic landscape of pediatric hemophagocytic lymphohistiocytosis. Blood. 2018;131(20):2145–52. https://doi.org/10.1182/blood-2018-01-834459.
8. Lenz D, Pahl J, Hauck F, Alameer S, Balasubramanian M, Baric I, et al. NBAS report on 500 patients from the Italian registry. J Allergy Clin Immunol. 2016;137(1):188-96.e4. https://doi.org/10.1016/j.jaci.2015.06.048.
9. Gadouyr-Levesque V, Dong L, Su R, Chen J, Zhang K, Risma KA, et al. Frequency spectrum of disease-causing variants in 1892 patients with suspected genetic HLH disorders. Blood Adv. 2020;4(12):2578–94. https://doi.org/10.1182/bloodadvances.2020001605.
10. Longman D, Jackson-Jones KA, Maslon MM, Murphy LC, Young RS, Stoddard JJ, et al. Identification of a localized nonsense-mediated decay pathway at the endoplasmic reticulum. Genes Dev. 2020;34(15–16):1075–88. https://doi.org/10.1101/gad.338061.120.
11. Aoki T, Ichimura S, Itoh A, Kuramoto M, Shinkawa T, Isobe T, et al. Identification of the neuroblastoma-amplified gene product as a component of the syntaxin 18 complex implicated in Golgi-endoplasmic reticulum retrograde transport. Mol Biol Cell. 2009;20(11):2639–49. https://doi.org/10.1091/mbc.E08-11-1104.
12. Albar RB, Alsaliman EF, Alsalim MA, Alnamlah A, Alhuzail A, Alejiani S. Natural killer cell deficiency in neuroblastoma amplified sequence gene mutation. Cureus. 2021;13(11):e19270. https://doi.org/10.7759/cureus.19270.
13. Lenz D, Pahl J, Hauck F, Alameer S, Balasubramanian M, Baric I, et al. NBAS variants are associated with quantitative and qualitative NK and B cell deficiency. J Clin Immunol. 2021;41(8):1781–93. https://doi.org/10.1007/s10875-021-01110-7.
14. Stauffer C, Peters B, Wagner M, Alameer S, Baric I, Brouse P, et al. Defining clinical subgroups and genotype-phenotype correlations in NBAS-associated disease across 110 patients. Genet Med. 2020;22(3):610–21. https://doi.org/10.1038/s41436-019-0698-4.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abbreviations
CTLs: Cytotoxic T lymphocytes; ER: Endoplasmic reticulum; HSCt: Hematopoietic stem cell transplantation; HLH: Hemophagocytic lymphohistiocytosis; NK: Natural killer; pHHLH: Presumed primary HLH; pHLH: Primary HLH; PPI: Protein-protein interaction, shRNA: Short hairpin RNA; WES: Whole-exome sequencing.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13045-022-03118-z.

Additional file 1: Methods and supplementary figures S1 to S6.
Additional file 2: Supplementary tables S1 to S7.

Supplementary tables S1 to S7.
Additional file 2: